RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer

By Yahoo! Finance | Sep 14, 2024 at 03:23 AM EST

Johnson & Johnson announced positive results from the Phase 3 MARIPOSA-2 study, showing RYBREVANT combined with chemotherapy led to significant and sustained improvement in post-progression outcomes for patients with previously treated EGFR-mutated non-small cell lung cancer.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.